Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Hanover - Delayed Quote • EUR Biomarin Pharmaceutical Inc (BM8.HA) Follow Compare 64.30 -2.56 (-3.83%) At close: March 11 at 5:25:16 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint. 1 Healthcare Stock to Target This Week and 2 to Turn Down Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 6.8%. This performance was disappointing since the S&P 500 climbed 1%. Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN). 4 Discounted PEG Stocks Offering the Best Returns to Value Investors Here we present four discounted PEG stocks that qualify our screening criteria, TAP, BMRN, DVN and JAZZ. Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait? KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth. Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio BOOT, STRL, DECK & BMRN's impressive interest coverage ratios highlight that these companies can withstand financial hardships. Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Statutory Profit Doesn't Reflect How Good BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings Are BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) just reported healthy earnings but the stock price didn't move much. Our... Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers. Is Auna S.A. (AUNA) Stock Outpacing Its Medical Peers This Year? Here is how Auna S.A. (AUNA) and BioMarin Pharmaceutical (BMRN) have performed compared to their sector so far this year. BMRN or CSLLY: Which Is the Better Value Stock Right Now? BMRN vs. CSLLY: Which Stock Is the Better Value Option? Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA BLUE and GILD are in the spotlight this week on key updates. Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates Investors in BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) had a good week, as its shares rose 9.7% to close at US$71.17... BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025, at 6:50 AM PT / 9:50 AM ET in Boston, MA. Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know. What To Expect From United Therapeutics’s (UTHR) Q4 Earnings Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and chief executive officer of Horizon Therapeutics, to the company's Board of Directors, effective Feb. 24, 2025. BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market. Oppenheimer upgrades BioMarin on long term outlook Investing.com -- Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the company's long-term financial outlook under new leadership. The firm set a new price target of $98 on BioMarin shares. Performance Overview Trailing total returns as of 3/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 Return BM8.HA S&P 500 YTD +0.66% -5.26% 1-Year -17.82% +8.87% 3-Year -8.90% +32.53%